Estimating the Impact and Cost of the WHO 2010 Recommendations for Antiretroviral Therapy

Table 3

Global results when ART eligibility is switched from CD4 count <200 to CD4 count <350 in 2010 while increasing coverage to 80% by 2015, by different d4T phase-out scenarios (2010–2015).

LMIC	CD4 < 200	CD4 < 350	Difference	% Change
Person years of ART	40,752,534	61,292,374	20,539,839	50%
AIDS deaths	8,180,609	6,501,483	−1,679,126	−21%
Life years of PLHIV	162,032,903	163,012,351	979,448	1%
New HIV infections	11,198,013	9,946,912	−1,251,101	−11%
Slower phase-out of d4T
ART costs (Millions of US$)	$25,027	$36,072	$11,045	44%
Testing costs (Millions of US$)	$1,282	$6,480	$5,198	406%
Total costs (Millions of US$)	$26,309	$42,552	$16,243	62%
Fast phase-out of d4T
ART costs (Millions of US$)	$25,678	$37,047	$11,369	44%
Testing costs (Millions of US$)	$1,282	$6,480	$5,198	406%
Total costs (Millions of US$)	$26,960	$43,527	$16,567	61%

Source: Authors’ calculations.